lunes, 24 de octubre de 2016


Boletín semanal de ofertas de empleo publico

Institución:Isntituto de Investigaciones Vall d'Hebron, Barcelona

We are currently looking for highly motivated candidates to apply for a Postdoctoral position funded by the 'Beatriu de Pinós' Program of the European Union and the Catalan Government ( The successful candidate will join the Group of Molecular Oncology of the Vall d'Hebron Research Institute ( before October the 1st 2015. The candidate will continue an established research line ( focusing on the role of the small GTPase RHOA in gastric cancer. The project will involve the use of a variety of cell/molecular biology techniques including in vitro systems, animal models and large tumor collections.


- Researchers who have obtained a doctorate from the 01/01/2008 and 31/12/2012.

- To have, at the time of joining the host organisation, a minimum of two years of postdoctoral experience outside Spain.

- Have at least one original publication as a first author or co-author.

- Not have resided or carried out their main activity in Spain for more than twelve months in the three years immediately prior to the submission of the application.


- Postdoctoral position for two years

- The gross salary will be euros 43,000 euros per year, including all Social Security expenses.

- Dynamic and stimulating research environment.


Please, contact Dr. Diego Arango before 7-Nov-2016: Reference: BdP2016

Información complementaria de la oferta:
Paulo Rodrigues, Irati Macaya, Sarah Bazzocco, Rocco Mazzolini, Elena Andretta, Higinio Dopeso, Silvia Mateo-Lozano, Josipa Bilic, Fernando Cartón-García, Rocio Nieto, Lucia Suárez-López, Elsa Afonso, Stefania Landolfi, Javier Hernandez-Losa, Kazuto Kobayashi; Santiago Ramón y Cajal, Josep Tabernero, Niall C. Tebbutt, John M. Mariadason, Simo Schwartz Jr, DIEGO ARANGO. RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. Nature Communications. 2014 Nov 21;5:5458.

Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Cajal SR, Mooseker MS, Mariadason JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Jr SS, ARANGO D. Brush border myosin Ia inactivation in gastric but not endometrial tumors. Int J Cancer. Int J Cancer. 2013 Apr 15;132(8):1790-9

Veronica Davalos, Lucia Suarez-Lopez, Julio Castano, Anthea Messent, Ibane Abasolo, Yolanda Fernandez, Angel Guerra-Moreno, Eloy Espin, Manel Armengol, Eva Musulen, Aurelio Ariza, Joan Sayos, DIEGO ARANGO and Simo Schwartz. hSMC, a Core Subunit of Human Condensin Complex, is a Novel Transcriptional Target of the Wnt Signaling Pathway and a New Therapeutic Target. J Biol Chem. 2012 Dec 21;287(52):43472-81

ARANGO D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM. Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer. Am J Pathol. 2012 Apr;180(4):1509-21.

Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón Y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, ARANGO D. Brush border Myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. Epub 2012 Jan 18.

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, ARANGO D. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clinical Cancer Research. 2010 Apr 15;16(8):2375-82.

Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng C, Moeslein G, Shibata D, Houlston RS, Lucassen A, Tomlinson IPM, Launonen V, Ristimäki A, ARANGO D, Karhu A, Sweeney HL, and Aaltonen LA. Unregulated smooth muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences, 2008; 105(14):5513-8. Epub 2008 Apr 7.

Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M, Imai K, Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz Jr. S, ARANGO D. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2007;26(2):308-11

Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, ARANGO D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006; 66(18):8943-8948

Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, ARANGO D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006;38(5):566-9

Paroder V, Spencer SR, Paroder M, ARANGO D, Schwartz Jr S, Mariadason JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences, 2006 May 9;103(19):7270-5

Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr., ARANGO D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research, 2005; 65(22):10170-3

No hay comentarios:

Publicar un comentario